Dignify Therapeutics
Research Triangle Park, US · Founded 2013 · Delaware LLC · 2 known investors
Find your way into Dignify Therapeutics
37 people in our graph share verified history with the Dignify Therapeutics team — schools, employers, funds. One of them is your warm intro.
Ashley Valentineunlockedknows Benny Ward · together at East Carolina University
×11knows the team · via East Carolina University
Dignify Therapeutics develops "on demand" drugs that trigger emptying of the bladder and/or bowel when a person chooses, aimed at restoring control of bowel and bladder function. It operates in the biotechnology and pharmaceutical space focused on therapeutics for people with impaired bladder and bowel control.
Founders & leadership
Dignify Therapeutics was founded in 2013 by Edward C Burgard and Karl Thor.
EC
Edward C BurgardCo-founder
KT
Karl ThorinCo-founder · Chief Scientific Officer
BW
Benny WardinChief Executive Officer, Co-Founder and Board Member2014–2017Benny Ward is an executive with experience spanning pharmaceutical and medical device companies at various stages, including serving as CEO of an early-stage venture-backed pharmaceutical development company, EVP of business development at a public specialty pharmaceutical firm, and leadership roles in device companies through IPO and acquisition.
Board
FE
DJ
Daniel J RiccaBoard director
EV
Ebrahim VersiBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$3.4M disclosed across 1 round · 2014
▶$3.4MraisedFeb 2015 · 7 investors · PharmaceuticalsRule 506(c)
▶$3.4MraisedFeb 2015 · 7 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Mary KatofiascPromoter
- Tatyana TouzovaPromoter
- Karl B ThorExecutive Officer, Director, Promoter
- Edward C BurgardExecutive Officer, Director, Promoter
- Benny WardExecutive Officer, Director, Promoter
- Daniel J RiccaDirector, Promoter
- Ebrahim VersiDirector, Promoter
- Florenta Aura KullmannPromoter
- Fred EshelmanDirector
- Venkateswarlu KarichetiPromoter
- Lesley MarsonPromoter
- Offering amount
- $3.4M
- Amount sold
- $3.4M
- Minimum investment
- $100K
- Proceeds to insiders
- $1M
- First sale
- Oct 2014
- Incorporated
- Limited Liability Company, Delaware, 2013
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Industries52 shared keywordsJ.P. Morgan is a global financial services firm serving corporations and individuals in more than 100 countries, offering investment research, tools, data, analytics, and advisory services. It supports institutional investors, asset and fund managers, hedge funds, broker dealers, and equity issuers with liquidity, fixed income strategies, and equity compensation solutions.
bio51 shared keywordsBIO is the world's largest advocacy association representing biotechnology companies and research institutions across the United States and 30+ other nations. The organization facilitates industry networking through events, conferences, and partnering software while providing cost-savings programs and advocacy services for member companies.
Forbion Capital44 shared keywordsA venture capital firm investing in biotech companies across all stages of pharmaceutical development, and in sustainable solutions across food, agriculture, materials, and environmental technologies through its BioEconomy strategy.
Mmm Online44 shared keywordsCore-Rx is an independent agency that provides pharmaceutical and healthcare marketing services, including campaign development, creative direction, and digital innovation. The agency serves pharmaceutical and biotech companies with strategic marketing, content creation, and technology integration services.
Syneos Health44 shared keywordsSyneos Health is a fully integrated biopharmaceutical solutions organization that provides clinical, medical affairs, and commercial services to help pharmaceutical companies accelerate market access and patient outcomes.
Companies competing with Dignify Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 18 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $541.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2020 | $394.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $244.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $901.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $299.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2019 | $269.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2016 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $275.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2015 | $224.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $199.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $159.3K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Dignify Therapeutics do?
- Dignify Therapeutics develops "on demand" drugs that trigger emptying of the bladder and/or bowel when a person chooses, aimed at restoring control of bowel and bladder function. It operates in the biotechnology and pharmaceutical space focused on therapeutics for people with impaired bladder and bowel control.
- Who founded Dignify Therapeutics?
- Dignify Therapeutics was founded by Edward C Burgard, Karl Thor in 2013.
- Who are Dignify Therapeutics's investors?
- Dignify Therapeutics's investors include Eshelman Ventures, LLC, RA Capital.
- How much funding has Dignify Therapeutics raised?
- Dignify Therapeutics has disclosed $3.4M raised across 1 round.
- Where is Dignify Therapeutics headquartered?
- Dignify Therapeutics is headquartered in Research Triangle Park, US.